Note sull'episodio
DOI: https://doi.org/10.1186/s40035-025-00465-w
Key Discussion Points:
1. Overview of Current Landscape
- Three FDA-approved second-generation antibodies: Aducanumab, Lecanemab, Donanemab
- Lecanemab recently received traditional FDA approval
- Represents validation of amyloid cascade hypothesis
2. Individual Antibody Profiles:
Aducanumab
- Derived from memory B cells of both healthy and cognitively impaired individuals
- Targets amyloid beta plaques (amino acids 3-7)
- Shows dose-dependent reduction in amyloid beta
- Notable occurrence of ARIA side effects
Lecanemab
- Derived from mouse antibody MA158
- Targets amyloid beta protofibr ...